S-304 PAH
Phase 2
- Conditions
- Pulmonary arterial hypertension (PAH)
- Registration Number
- JPRN-jRCT2080221493
- Lead Sponsor
- IPPON SHINYAKU CO., LTD. / Actelion Pharmaceuticals Japan Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Idiopathic pulmonary arterial hypertension (IPAH)
Heritable pulmonary arterial hypertension (HPAH)
Drug- and Toxin-induced pulmonary arterial hypertension
PAH associated with one of the following;
a) connective tissue disease
b) congenital heart disease (At least one year should be elapsed after pulmonary shunt at the time of each baseline measurement.)
c) HIV infection
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method